Literature DB >> 29576302

Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.

Junko Watanabe1, Naoki Furuya2, Yutaka Fujiwara3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29576302     DOI： 10.1016/j.jtho.2017.11.125

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

1.  MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.

Authors:  Sudarshan R Iyer; Igor Odintsov; Adam J Schoenfeld; Evan Siau; Marissa S Mattar; Elisa de Stanchina; Inna Khodos; Alexander Drilon; Gregory J Riely; Marc Ladanyi; Romel Somwar; Monika A Davare
Journal:  Mol Cancer Res       Date:  2022-05-04       Impact factor: 6.333

2.  Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis.

Authors:  Ken Masuda; Yutaka Fujiwara; Yuki Shinno; Takaaki Mizuno; Jun Sato; Ryo Morita; Yuji Matsumoto; Shuji Murakami; Yasushi Goto; Shintaro Kanda; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

3.  Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.

Authors:  Yuka Kato; Kiichiro Ninomiya; Kadoaki Ohashi; Shuta Tomida; Go Makimoto; Hiromi Watanabe; Kenichiro Kudo; Shingo Matsumoto; Shigeki Umemura; Koichi Goto; Eiki Ichihara; Takashi Ninomiya; Toshio Kubo; Akiko Sato; Katsuyuki Hotta; Masahiro Tabata; Shinichi Toyooka; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  Cancer Sci       Date:  2018-09-11       Impact factor: 6.716

4.  Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.

Authors:  Yongchang Zhang; Zhe Huang; Liang Zeng; Xiangyu Zhang; Yizhi Li; Qinqin Xu; Haiyan Yang; Analyn Lizaso; Chunwei Xu; Jun Liu; Wenxian Wang; Zhengbo Song; Sai-Hong Ignatius Ou; Nong Yang
Journal:  NPJ Precis Oncol       Date:  2022-03-31

5.  BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.

Authors:  Juan Li; Qifeng Wang; Jun Ge; Yuke Tian; Wenxiu Yao
Journal:  Oncologist       Date:  2021-11-09

Review 6.  The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.

Authors:  Longyao Zhang; Linpeng Zheng; Qiao Yang; Jianguo Sun
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

Review 7.  ROS1-dependent cancers - biology, diagnostics and therapeutics.

Authors:  Alexander Drilon; Chelsea Jenkins; Sudarshan Iyer; Adam Schoenfeld; Clare Keddy; Monika A Davare
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

8.  Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report.

Authors:  Tao Yang; Rui Xu; Bing Yan; Fang Li; Hui Liu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.